Month: March 2020

                                      BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 02 Mar 2020.Estimated NAVNAV and returns are calculated net of management and performance feesMarket informationTransactions in own securities purchased into treasury                                                      BGHL CapitalEstimated BG Fund NAVThe Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management, LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe...

Press releaseParis La Défense, 3 march 20202019 annual resultsRevenue up 18% and EBITDA up 12%Continued increase in the share of renewables in the energy mix, to 67%ESG performance: entry into the Top 20 of the energy sector, with an 8-point gain in the Vigeo Eiris ratingAlbioma’s Board of Directors, chaired by Frédéric Moyne, met on 02 March 2020 and approved the Group’s consolidated financial statements for the 2019 financial year.“We are today reporting solid results, with revenues up 18% to €505.7 million and EBITDA up 12% to €182.9 million. These results demonstrate the expertise of our teams and Albioma’s long-term robustness thanks to the good performance of our thermal and solar power plants, combined with an excellent operational year for the Group’s new biomass facilities in overseas France and...

As Coronavirus outbreak continues and still mongers fears all throughout the globe, an Ex-White House Advisor (He works with President Donald Trump for two weeks as the latter’s Communications Director) and investor Anthony Scaramucci said that he was never been more defensive on equities. Just this Monday, February 24. 2020 investors experienced the worsens one-day decline on stocks in the past two years due to fear of the outbreak of the Novel Coronavirus (COVID-19). With another early rally happened last Tuesday made investors scamper to a safer harbor. Speaking about why is the trading conditions nowadays so volatile to Yahoo Finance Newsroom ‘On The Move’, Scaramucci listed some of his concerns; why the repo market’s seizing up its last fall? And, so is why the big banks is having less liquidity? He explained that a typical electronic...

Geneva, Switzerland, March 3, 2020 – Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the appointment of one of the world’s leading and most successful neuroscience drug research and developers, Darryle D. Schoepp PhD, as Chairman of its newly formed scientific advisory board (SAB). Dr. Schoepp has over thirty years experience in the field, including 20 years at Eli Lilly as a scientist and leader of the neuroscience research department, and 11 years at Merck as the neuroscience research therapeutic area leader. During his career, Dr. Schoepp has been involved in the discovery of over 20 novel first in class agents for psychiatric and neurological diseases.“Darryle has been pioneering novel approaches in...

Die negative Marktentwicklung führt beim Technologieunternehmen zu einem Rückgang der Geschäftszahlen im Jahr 2019. So reduziert sich der Umsatz um 6.9 Prozent auf CHF 632.7 Mio.; das operative Ergebnis (EBIT) beträgt CHF 18.9 Mio. Die operative Marge beläuft sich auf 3.0 Prozent, das Nettoergebnis auf CHF 10.7 Mio. Feintool bereitet sich mit technischen Innovationen auf eine Erholung des Marktes vor, dies in einem für die kommende Dekade attraktiven globalen Automobilmarkt.Die negative Marktentwicklung unserer Industrie, welche sich seit Beginn des Geschäftsjahres abzeichnete, hatte Folgen für die Feintool-Gruppe. Nach zehn Jahren weltweitem Wachstum kam es nun zu einer Abschwächung, die mit zusätzlichen globalen Trends unserer Industrie einherging. Die Entwicklung der weltweiten Konjunktur und somit des globalen Automobilmarktes –...

Negative market trends caused the technology group’s performance to decline in 2019. As such, net sales fell by 6.9% to CHF 632.7 million; earnings before interest and taxes (EBIT) totaled CHF 18.9 million. The groups’s operating margin stood at 3.0% and net income at CHF 10.7 million. With technical innovations Feintool prepares for a recovery in a global automotive market, which is expected to be attractive over the coming decade.The negative market trend in our industry that has been apparent since the beginning of the financial year had consequences for the Feintool Group. After ten years of global growth, a slowdown has now occurred that has been accompanied by additional global trends in our industry. The global economy, and with it the global automotive market – with all of Feintool’s applications in the vehicle including safety,...

Communiqué de presseParis La Défense, le 3 mars 2020Résultats annuels 2019Chiffre d’affaires en hausse de 18 %, et EBITDA en croissance de 12 %Augmentation continue de la part du renouvelable dans le mix, à 67 %Performance ESG : entrée dans le Top 20 du secteur énergie avec un gain de 8 points sur la notation Vigeo EirisLe Conseil d’Administration d’Albioma, réuni le 2 mars 2020 sous la présidence de Frédéric Moyne, a arrêté les comptes consolidés du Groupe pour l’exercice 2019.« Nous publions ce jour des résultats solides, avec un chiffre d’affaires en hausse de 18 % à 505,7 millions d’euros et un EBITDA en croissance de 12 % à 182,9 millions d’euros. Ces résultats témoignent du savoir-faire de nos équipes et de la robustesse d’Albioma sur la durée grâce aux bonnes performances de nos centrales thermiques et solaires, associées à une...

(Bergen, 3. mars 2020) Mowi og Tidal, X sitt havbruks- og bærekraft team, utvikler og tester ny teknologi sammen.De siste tre årene har Mowi, sammen med Alphabet X sitt datterselskap, Tidal, utviklet og testet et nytt sensorsystem. Etter en omfattende forsknings- og utviklingsfase med feltprøving og datainnsamling, er prosjektet nå klart for kommersiell validering. Mowi skal nå installere teknologien på en rekke anlegg i Norge.Tidal har utviklet et avansert sensorsystem for bruk i havbruksnæringen med tilhørende programvare som samler sanntids-informasjon om vektfordeling, fôringskontroll og automatisk lusetelling. Ved å ta i bruk ny kamerateknologi og maskinlæring kan systemet oppfatte og modellere fiskens atferd, miljøforhold og laksens helse over tid.− Mowi sin visjon er å lede den blå revolusjonen. Som verdens største havbruksselskap...

(Bergen, 3 March 2020) Mowi works with Tidal, X’s ocean health and sustainably team, to test and research new technologies.Over the last three years, Mowi has been researching and testing a new sensing system developed by Tidal at Alphabet’s X. After an extensive research and development period involving field testing and data collection, the project is now ready for commercial validation and Mowi will roll out the technology to multiple sites across Norway.Tidal has been developing an advanced underwater sensing and software analysis platform that gathers intelligence on real-time growth, weight distribution, feeding control, and automatic lice counting for salmon. Using a combination of new camera technology as well as machine learning and machine perception, Tidal’s system is able to track and model fish behaviours, environmental conditions,...

Abpro to receive up to $1.1 billion, including a $30 million upfront equity investment, clinical funding, milestones, and royaltiesAbpro grants exclusive license to Abpro Bio, formerly named Ugint Co. Ltd, to develop and commercialize ABP-100 and ABP-201 in Asian markets, including Greater China, Japan, and South KoreaTwo Bispecific Antibody Candidates included are for Immuno-Oncology and OphthalmologyWOBURN, Mass., March 03, 2020 (GLOBE NEWSWIRE) — Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, today announced the formation of a strategic partnership to advance two bispecific antibodies in key Asian markets including Greater China, Japan, and South Korea.The strategic partnership was formed with Abpro Bio Co....